Why the study?
Coronary angiography is an increasing diagnostic procedure in Belgium, and this analysis evaluated its financial aspects in a large tertiary hospital to establish if current reimbursement is appropriate.
Current reimbursement for diagnostic coronary angiography in Belgium may be insufficient to cover hospital costs, requiring a high daily volume to break even.
Answers are grounded in this paper and cite their sources.
Insufficient reimbursement may threaten Belgian cathlab viability at typical volumes; leaves open whether tariff adjustments are needed.
Coronary angiography (CA) is an increasing diagnostic procedure in Belgium. The aim of this analysis was to look at the financial aspects of CA in a large tertiary Belgium hospital to establish if current reimbursement is appropriate. For the analysis of costs we considered the use of the catheterisation laboratory, personnel costs and material costs during multiple weekly periods in the spring of 2023. We calculated that one cathlab needs to perform 8.21 CA's to equal incomes with costs. To allow for a small positive income (200€) for the hospital/cardiologist 9 procedures per cathlab day are required. Our hospital performs a 7 (mean) ± 0.75 (standard deviation) of CA's per cathlab day and therefore does not reach this financial break-even point. Our calculations are on the safe side, since coronary physiological interrogation with fractional flow reserve (FFR) was excluded from this analysis. Nevertheless, this is a cost-effective technique for which no extra reimbursement is foreseen in the current Belgium system.
No takes yet. Share an insight, caveat, or question.
Minten et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: